Phase I Study of HSK42360 in Solid Tumors With BRAF V600 Mutation

NCT06536400 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

316

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumors

Interventions

DRUG: HSK42360

Sponsor

Haisco Pharmaceutical Group Co., Ltd.